Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.

Adegbola AJ, Abutaima R, Adeagbo BA, Bolarinwa RA, Olagunju AE, Siccardi M, Owen A, Bolaji OO.

Pharmacogenet Genomics. 2020 Mar 30. doi: 10.1097/FPC.0000000000000401. [Epub ahead of print]

PMID:
32209837
2.

Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach.

Adehin A, Igbinoba SI, Soyinka JO, Onyeji CO, Babalola CP, Bolaji OO.

Curr Ther Res Clin Exp. 2019 Sep 12;91:33-38. doi: 10.1016/j.curtheres.2019.100567. eCollection 2019.

3.

Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice.

Adepiti AO, Adeagbo BA, Adehin A, Bolaji OO, Elujoba AA.

Eur J Drug Metab Pharmacokinet. 2020 Feb;45(1):81-88. doi: 10.1007/s13318-019-00583-7.

PMID:
31642009
4.

Pharmacogenomics in the Nigerian population: the past, the present and the future.

Bolaji OO, Adehin A, Adeagbo BA.

Pharmacogenomics. 2019 Aug;20(12):915-926. doi: 10.2217/pgs-2019-0046.

PMID:
31453771
5.

Vitamin A deficiency among under-five Nigerian children with diarrhoea.

Abolurin OO, Adegbola AJ, Oyelami OA, Adegoke SA, Bolaji OO.

Afr Health Sci. 2018 Sep;18(3):737-742. doi: 10.4314/ahs.v18i3.32.

6.

Evaluation of the impact of CYP1A2 induction by charbroiled meal on metabolic phenotype.

Anumu George J, Adehin A, Bolaji OO.

Clin Nutr ESPEN. 2018 Oct;27:96-99. doi: 10.1016/j.clnesp.2018.06.002. Epub 2018 Jun 28.

PMID:
30144900
7.

Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers.

Olawoye OS, Adeagbo BA, Bolaji OO.

J Clin Pharm Ther. 2018 Oct;43(5):626-632. doi: 10.1111/jcpt.12725. Epub 2018 Jun 19.

PMID:
29920710
8.

Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?

Adehin A, Adeagbo BA, Kennedy MA, Bolaji OO, Olugbade TA, Bolarinwa RA, Durosinmi MA.

Leuk Lymphoma. 2019 Jan;60(1):216-221. doi: 10.1080/10428194.2018.1466291. Epub 2018 May 9.

PMID:
29741432
9.

Prevalence of Vitamin A deficiency among under-five children in South-Western Nigeria.

Abolurin OO, Adegbola AJ, Oyelami OA, Adegoke SA, Bolaji OO.

Niger Postgrad Med J. 2018 Jan-Mar;25(1):13-16. doi: 10.4103/npmj.npmj_20_18.

10.

Thiopurine S-methyltransferase activity in Nigerians: phenotypes and activity reference values.

Adehin A, Bolaji OO.

BMC Res Notes. 2018 Feb 14;11(1):129. doi: 10.1186/s13104-018-3237-5.

11.

Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.

Adeagbo BA, Olugbade TA, Durosinmi MA, Bolarinwa RA, Ogungbenro K, Bolaji OO.

J Clin Pharmacol. 2017 Dec;57(12):1554-1563. doi: 10.1002/jcph.953. Epub 2017 Jun 15.

PMID:
28618035
12.

Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population.

Adehin A, Bolaji OO, Kennedy MA.

Drug Metab Pharmacokinet. 2017 Jun;32(3):189-191. doi: 10.1016/j.dmpk.2016.09.001. Epub 2016 Sep 14.

PMID:
28427759
13.

Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population.

Adehin A, Bolaji OO, Maggo S, Kennedy MA.

Drug Metab Pers Ther. 2017 Mar 1;32(1):39-47. doi: 10.1515/dmpt-2016-0041.

PMID:
28231062
14.

Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.

Adeagbo BA, Bolaji OO, Olugbade TA, Durosinmi MA, Bolarinwa RA, Masimirembwa C.

J Clin Pharm Ther. 2016 Oct;41(5):546-51. doi: 10.1111/jcpt.12424. Epub 2016 Jul 18.

PMID:
27426203
15.

Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model.

Adepiti AO, Elujoba AA, Bolaji OO.

Pharm Biol. 2016 Oct;54(10):2298-303. doi: 10.3109/13880209.2016.1155626. Epub 2016 Apr 8.

PMID:
27057621
16.

Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.

Adehin A, Bolaji OO.

Drug Metab Pers Ther. 2015 Sep;30(3):203-10. doi: 10.1515/dmpt-2015-0001.

PMID:
26098700
17.

Distribution of xanthine oxidase activity in a Nigerian population.

Adehin A, Bolaji OO.

Eur J Clin Pharmacol. 2015 Jun;71(6):687-690. doi: 10.1007/s00228-015-1852-9. Epub 2015 May 5.

PMID:
25939710
19.

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

Olagunju A, Bolaji OO, Amara A, Waitt C, Else L, Soyinka J, Adeagbo B, Adejuyigbe E, Siccardi M, Back D, Owen A, Khoo S.

J Antimicrob Chemother. 2015 Feb;70(2):555-61. doi: 10.1093/jac/dku420. Epub 2014 Oct 17.

20.

In vivo antimalarial evaluation of MAMA decoction on Plasmodium berghei in mice.

Adepiti AO, Elujoba AA, Bolaji OO.

Parasitol Res. 2014 Feb;113(2):505-11. doi: 10.1007/s00436-013-3680-0. Epub 2013 Nov 22.

PMID:
24271081
21.

Establishment of a biobank and pharmacogenetics database of African populations.

Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN, Masimirembwa CM.

Eur J Hum Genet. 2008 Jul;16(7):780-3. doi: 10.1038/ejhg.2008.49. Epub 2008 Apr 2. No abstract available.

22.

Absolute bioavailability of quinine formulations in Nigeria.

Babalola CP, Bolaji OO, Ogunbona FA, Ezeomah E.

Afr J Med Med Sci. 2004 Sep;33(3):185-9.

PMID:
15819461
23.

Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy.

Chukwuani MC, Bolaji OO, Onyeji CO, Makinde ON, Ogunbona FA.

Trop Med Int Health. 2004 May;9(5):601-5.

24.

Polymorphic oxidative metabolism of proguanil in a Nigerian population.

Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA.

Eur J Clin Pharmacol. 2002 Nov;58(8):543-5. Epub 2002 Sep 24.

PMID:
12451432
25.

Pharmacokinetics of quinine in African patients with acute falciparum malaria.

Babalola CP, Bolaji OO, Ogunbona FA, Sowunmi A, Walker O.

Pharm World Sci. 1998 Jun;20(3):118-22.

PMID:
9618735
26.

Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients.

Islam SI, Masuda QN, Bolaji OO, Shaheen FM, Sheikh IA.

Ther Drug Monit. 1996 Oct;18(5):624-6.

PMID:
8885130
27.

Pharmacokinetics and bioavailability of drotaverine in humans.

Bolaji OO, Onyeji CO, Ogundaini AO, Olugbade TA, Ogunbona FA.

Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):217-21.

PMID:
8980918
28.

Relationship between plasma and saliva quinine levels in humans.

Babalola CP, Bolaji OO, Ogunbona FA, Dixon PA.

Ther Drug Monit. 1996 Feb;18(1):30-3.

PMID:
8848817
29.

Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation.

Coutts RT, Bolaji OO, Su P, Baker GB.

Drug Metab Dispos. 1994 Sep-Oct;22(5):756-60.

PMID:
7835228
30.

High-performance liquid chromatographic method for the determination of drotaverine in human plasma and urine.

Bolaji OO, Onyeji CO, Ogungbamila FO, Ogunbona FA, Ogunlana EO.

J Chromatogr. 1993 Dec 8;622(1):93-7.

PMID:
8120119
31.

Metabolism of trimipramine in vitro by human CYP2D6 isozyme.

Bolaji OO, Coutts RT, Baker GB.

Res Commun Chem Pathol Pharmacol. 1993 Oct;82(1):111-20.

PMID:
8272570
32.

Column liquid chromatographic analysis of quinine in human plasma, saliva and urine.

Babalola CP, Bolaji OO, Dixon PA, Ogunbona FA.

J Chromatogr. 1993 Jun 23;616(1):151-4.

PMID:
8376486
33.

Characterization of the principal metabolite of quinine in human urine by 1H-n.m.r. spectroscopy.

Bolaji OO, Babalola CP, Dixon PA.

Xenobiotica. 1991 Apr;21(4):447-50.

PMID:
1897244
34.

Excretion of chloroquine and desethylchloroquine in human milk.

Ogunbona FA, Onyeji CO, Bolaji OO, Torimiro SE.

Br J Clin Pharmacol. 1987 Apr;23(4):473-6.

35.

Liquid chromatographic analysis of chloroquine and desethylchloroquine in human plasma, saliva and urine.

Ogunbona FA, Onyeji CO, Lawal AA, Chukwuani CM, Bolaji OO.

J Chromatogr. 1986 Aug 2;380(2):425-30. No abstract available.

PMID:
3760072

Supplemental Content

Loading ...
Support Center